US Bancorp DE Sells 2,529 Shares of Catalent, Inc. (NYSE:CTLT)

US Bancorp DE reduced its position in Catalent, Inc. (NYSE:CTLT) by 35.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,664 shares of the company’s stock after selling 2,529 shares during the quarter. US Bancorp DE’s holdings in Catalent were worth $282,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CTLT. Millennium Management LLC lifted its holdings in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after acquiring an additional 2,299,784 shares during the period. Magnetar Financial LLC acquired a new stake in Catalent during the first quarter valued at approximately $56,429,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Catalent in the 2nd quarter valued at approximately $29,172,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Catalent by 2,792.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after buying an additional 498,540 shares during the period. Finally, Bank of Montreal Can boosted its stake in Catalent by 222.0% in the 2nd quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock valued at $36,219,000 after buying an additional 444,084 shares in the last quarter.

Wall Street Analyst Weigh In

CTLT has been the subject of a number of analyst reports. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a report on Wednesday, November 6th. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Stock Down 0.2 %

Shares of CTLT opened at $59.15 on Thursday. The business’s fifty day moving average price is $59.89 and its two-hundred day moving average price is $58.16. The firm has a market capitalization of $10.74 billion, a price-to-earnings ratio of -26.17, a PEG ratio of 2.36 and a beta of 1.16. Catalent, Inc. has a 52 week low of $34.92 and a 52 week high of $61.20. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) EPS. Catalent’s revenue was up 4.2% on a year-over-year basis. On average, analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is currently owned by insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.